Q&A with Bruce Bebo, Executive Vice President, Research
April 3, 2015
FasterCures established The Research Acceleration and Innovation Network (TRAIN) to create opportunities for medical research innovators to discuss and tackle the challenges that cut across diseases. It is a group of unique nonprofit foundations that fund medical research across a spectrum of diseases. They represent organizations that are the engine behind innovation in disease research - collaborative, mission-driven, strategic in their allocation of resources, and results-oriented. To highlight the entrepreneurial spirit of TRAIN participating organizations, TRAIN publishes an Innovator Spotlight column which features outstanding organizational work in driving medical research. In this month’s spotlight, Bruce Bebo, executive vice president of research, discusses how the National MS Society has been a catalyst for most major advancements in MS research for the past 66 years, including laying the groundwork for all the current FDA approved disease-modifying therapies.
About Multiple Sclerosis
Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.